Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling